詳細検索

詳細検索

お問い合わせ

Global Swine Live Vaccine Market Outlook, InDepth Analysis & Forecast to 2032

Global Swine Live Vaccine Market Outlook, InDepth Analysis & Forecast to 2032


豚用生ワクチンの世界市場 2026-2032年

The global Swine Live Vaccine market is projected to grow from US$ 962 million in 2025 to US$ 1265 million by 2032, at a CAGR of 4.2% (2026-2032), driven by critical product segments and diverse en... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月15日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Swine Live Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Swine Live Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Swine Live Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Swine Live Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Swine Live Vaccine Revenue, 2025
Table 13. Global Swine Live Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Swine Live Vaccine Companies Headquarters
Table 15. Global Swine Live Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Swine Live Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Swine Live Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 21. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 22. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2021-2026
Table 23. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Swine Live Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Swine Live Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Swine Live Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Swine Live Vaccine Growth Accelerators and Market Barriers
Table 31. North America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Swine Live Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Swine Live Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Swine Live Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Swine Live Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Swine Live Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Zoetis Corporation Information
Table 41. Zoetis Description and Major Businesses
Table 42. Zoetis Product Features and Attributes
Table 43. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Zoetis Revenue Proportion by Product in 2025
Table 45. Zoetis Revenue Proportion by Application in 2025
Table 46. Zoetis Revenue Proportion by Geographic Area in 2025
Table 47. Zoetis Swine Live Vaccine SWOT Analysis
Table 48. Zoetis Recent Developments
Table 49. MSD Animal Health(Merck) Corporation Information
Table 50. MSD Animal Health(Merck) Description and Major Businesses
Table 51. MSD Animal Health(Merck) Product Features and Attributes
Table 52. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 54. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 55. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 56. MSD Animal Health(Merck) Swine Live Vaccine SWOT Analysis
Table 57. MSD Animal Health(Merck) Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Swine Live Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Swine Live Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Bioveta Corporation Information
Table 77. Bioveta Description and Major Businesses
Table 78. Bioveta Product Features and Attributes
Table 79. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Bioveta Revenue Proportion by Product in 2025
Table 81. Bioveta Revenue Proportion by Application in 2025
Table 82. Bioveta Revenue Proportion by Geographic Area in 2025
Table 83. Bioveta Swine Live Vaccine SWOT Analysis
Table 84. Bioveta Recent Developments
Table 85. HIPRA Corporation Information
Table 86. HIPRA Description and Major Businesses
Table 87. HIPRA Product Features and Attributes
Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. HIPRA Recent Developments
Table 90. Syva Corporation Information
Table 91. Syva Description and Major Businesses
Table 92. Syva Product Features and Attributes
Table 93. Syva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Syva Recent Developments
Table 95. Elanco Animal Health Corporation Information
Table 96. Elanco Animal Health Description and Major Businesses
Table 97. Elanco Animal Health Product Features and Attributes
Table 98. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Elanco Animal Health Recent Developments
Table 100. TECON Biology Corporation Information
Table 101. TECON Biology Description and Major Businesses
Table 102. TECON Biology Product Features and Attributes
Table 103. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. TECON Biology Recent Developments
Table 105. VETVACO Corporation Information
Table 106. VETVACO Description and Major Businesses
Table 107. VETVACO Product Features and Attributes
Table 108. VETVACO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. VETVACO Recent Developments
Table 110. Harbin Pharmaceutical Group Corporation Information
Table 111. Harbin Pharmaceutical Group Description and Major Businesses
Table 112. Harbin Pharmaceutical Group Product Features and Attributes
Table 113. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Harbin Pharmaceutical Group Recent Developments
Table 115. CAHIC Corporation Information
Table 116. CAHIC Description and Major Businesses
Table 117. CAHIC Product Features and Attributes
Table 118. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. CAHIC Recent Developments
Table 120. Jinyu Bio-Technology Corporation Information
Table 121. Jinyu Bio-Technology Description and Major Businesses
Table 122. Jinyu Bio-Technology Product Features and Attributes
Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Jinyu Bio-Technology Recent Developments
Table 125. Pulike Corporation Information
Table 126. Pulike Description and Major Businesses
Table 127. Pulike Product Features and Attributes
Table 128. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Pulike Recent Developments
Table 130. WINSUN Corporation Information
Table 131. WINSUN Description and Major Businesses
Table 132. WINSUN Product Features and Attributes
Table 133. WINSUN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. WINSUN Recent Developments
Table 135. DHN Corporation Information
Table 136. DHN Description and Major Businesses
Table 137. DHN Product Features and Attributes
Table 138. DHN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. DHN Recent Developments
Table 140. HVRI Corporation Information
Table 141. HVRI Description and Major Businesses
Table 142. HVRI Product Features and Attributes
Table 143. HVRI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. HVRI Recent Developments
Table 145. Jilin Zhengye Corporation Information
Table 146. Jilin Zhengye Description and Major Businesses
Table 147. Jilin Zhengye Product Features and Attributes
Table 148. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Jilin Zhengye Recent Developments
Table 150. Wuhan Keqian Biology Corporation Information
Table 151. Wuhan Keqian Biology Description and Major Businesses
Table 152. Wuhan Keqian Biology Product Features and Attributes
Table 153. Wuhan Keqian Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Wuhan Keqian Biology Recent Developments
Table 155. Sinopharm Animal Health Corporation Information
Table 156. Sinopharm Animal Health Description and Major Businesses
Table 157. Sinopharm Animal Health Product Features and Attributes
Table 158. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Sinopharm Animal Health Recent Developments
Table 160. Technologies, Platforms and Infrastructure
Table 161. Distributors List
Table 162. Market Trends and Market Evolution
Table 163. Market Drivers and Opportunities
Table 164. Market Challenges, Risks, and Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. PRRS Vaccines Product Picture
Figure 3. Classical Swine Fever Vaccines Product Picture
Figure 4. Pseudorabies Vaccines Product Picture
Figure 5. Others Product Picture
Figure 6. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Monovalent Live Vaccines Product Picture
Figure 8. Bivalent Live Vaccines Product Picture
Figure 9. Multivalent Live Vaccines Product Picture
Figure 10. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Lyophilized Live Vaccines Product Picture
Figure 12. Liquid Live Vaccines Product Picture
Figure 13. Others Product Picture
Figure 14. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Piglets
Figure 16. Growing and Finishing Pigs
Figure 17. Breeding Sows and Gilts
Figure 18. Breeding Boars
Figure 19. Others
Figure 20. Swine Live Vaccine Report Years Considered
Figure 21. Global Swine Live Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 23. Global Swine Live Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global Swine Live Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global Swine Live Vaccine Revenue-Based Market Share Ranking (2025)
Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 27. PRRS Vaccines Revenue-Based Market Share by Player in 2025
Figure 28. Classical Swine Fever Vaccines Revenue-Based Market Share by Player in 2025
Figure 29. Pseudorabies Vaccines Revenue-Based Market Share by Player in 2025
Figure 30. Others Revenue-Based Market Share by Player in 2025
Figure 31. Global Swine Live Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Swine Live Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 33. Global Swine Live Vaccine Revenue-Based Market Share by Dosage Form (2021-2032)
Figure 34. Global Swine Live Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 37. North America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 39. Canada Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 40. Mexico Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 41. Europe Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 43. Europe Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 45. France Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 46. U.K. Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 47. Italy Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 48. Russia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 53. Japan Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 54. South Korea Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Australia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 56. India Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 60. Philippines Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 61. Singapore Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 64. Central and South America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 66. Argentina Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 71. Israel Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 72. Egypt Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 73. South Africa Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 74. Swine Live Vaccine Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Swine Live Vaccine market is projected to grow from US$ 962 million in 2025 to US$ 1265 million by 2032, at a CAGR of 4.2% (2026-2032), driven by critical product segments and diverse end‑use applications.

Swine Live Vaccines are veterinary biological products containing live viruses, bacteria, or other microorganisms that have been attenuated while retaining limited replication capability and immunogenicity and are used to induce active immunity against specific infectious diseases in pigs. The major disease categories include PRRS Vaccines, Classical Swine Fever Vaccines, Pseudorabies Vaccines, and Others. By Antigen Combination, the product is classified into Monovalent Live Vaccines, Bivalent Live Vaccines, and Multivalent Live Vaccines; by Dosage Form, into Lyophilized Live Vaccines, Liquid Live Vaccines, and Others, with lyophilized formulations being the most widely commercialized. Manufacturing generally uses master- and working-seed systems followed by cell culture or other suitable biological substrate propagation, attenuated-strain cultivation, harvesting, stabilization, lyophilization or liquid filling, and potency testing. Core parameters include TCID50, PFU or CFU potency, attenuation stability, genetic stability, onset and duration of immunity, maternal-antibody interference, and storage conditions.

Key Findings
The average industry gross margin in 2025 is approximately 40%–60%.

PRRS Vaccines represent the largest value segment, with representative modified-live products providing approximately 10^4.8 TCID50 per dose at an injection volume of around 1–2 mL.

Piglets represent the largest downstream application, with mainstream modified-live PRRS products commonly administered from one day to three weeks of age or older.

Zoetis, MSD Animal Health, Boehringer Ingelheim, Ceva Santé Animale, and HIPRA are positioned among the major global suppliers.

Market Trends
The product is evolving from conventionally attenuated strains toward genetically engineered attenuation, improved genetic stability, needle-free intradermal administration, and digital vaccination management. PRRS remains the most innovation-intensive field. Ceva's next-generation PRRSV2 modified-live platform uses reverse genetics and Synthetic Attenuated Virus Engineering to improve genetic stability and heterologous protection, while HIPRA combines a lyophilized PRRS live vaccine with 0.2 mL needle-free intradermal administration, RFID labeling, and digital vaccination records. For Classical Swine Fever, conventional C-strain vaccines remain established, but DIVA-compatible live-marker technologies and molecular differentiation are increasingly important in eradication-oriented regions.

Market Dynamics
Drivers
Demand for the product is mainly driven by large-scale swine production, persistent endemic PRRS, piglet health management, and protection of reproductive performance in breeding herds. PRRSV is endemic across most major swine-producing regions and can cause reproductive failure, piglet mortality, respiratory disease, and reduced growth, making vaccination an important component of long-term herd control together with internal biosecurity. Modified-live PRRS vaccines address both respiratory and reproductive manifestations. Fostera PRRS can be used in susceptible pigs one day of age or older, Prevacent PRRS in pigs two weeks of age or older, and Ingelvac PRRS MLV is commonly used in piglets three weeks of age or older as well as replacement gilts and adult sows, creating demand across multiple production stages.

Restraints
The main restraints are vaccine-strain shedding, recombination and genetic-stability concerns, together with substantial differences in circulating strains and herd immunity. Modified-live PRRS strains can replicate and be shed by vaccinated animals, and both Zoetis and Elanco warn that vaccine virus may be transmitted to pigs in direct or indirect contact with vaccinated animals, making such products unsuitable for herds intended to remain PRRS-negative. PRRSV itself has high genetic diversity and recombination potential, complicating vaccination programs where field and vaccine strains coexist. Conventional Classical Swine Fever live vaccines also have limitations during eradication because standard antibody testing cannot always distinguish infected from vaccinated animals, increasing interest in DIVA technologies and post-vaccination surveillance.

Opportunities
Future opportunities are concentrated in next-generation modified-live PRRS platforms, needle-free intradermal vaccination, DIVA live-marker vaccines, and Bivalent or Multivalent products. HIPRA's UNISTRAIN PRRS can be administered as a 2 mL intramuscular dose or a 0.2 mL intradermal dose and can be integrated with digital vaccination devices. Ceva's next-generation PRRSV2 platform differentiates through reverse genetics and engineered attenuation. In Antigen Combination, Bivalent and Multivalent live vaccines can reduce handling and administration frequency. Bioveta commercializes a live Bivalent product combining Classical Swine Fever and swine erysipelas, containing at least approximately 1×10^9 live Erysipelothrix organisms and at least 10^5 PD50 of Classical Swine Fever antigen. Platforms combining multi-disease protection, low-dose administration, and digital traceability offer high value potential.

Challenges
The core challenge is simultaneously achieving adequate attenuation, stable immunogenicity, and low risk of recombination or reversion to virulence. PRRSV comprises the distinct PRRSV-1 and PRRSV-2 species, with substantial internal genetic diversity, and multiple variants may circulate within the same farm, limiting the ability of a single vaccine to cover every heterologous challenge. Modified-live strains can also participate in recombination, requiring strict internal biosecurity and disciplined vaccination programs. Classical Swine Fever live vaccines similarly require long-term validation of master-seed purity, genetic stability, and reversion-to-virulence risk. WOAH requires production under a seed-lot system and has strengthened safety requirements for conventional and live-marker vaccines. Future competition will increasingly depend on genomic-stability validation, cross-protection data, and post-market surveillance.

Industry Chain Analysis
The upstream supply chain mainly includes master and working seed stocks, animal cell lines and culture media, bioreactors, stabilizers, lyophilization protectants, sterile diluents, culture consumables, glass vials, and cold-chain packaging. Seed purity, cell-substrate safety, and culture yield determine fundamental product quality. Midstream activities include attenuated-strain selection or engineering, cell-culture propagation, virus or bacterial harvesting, clarification and concentration, potency standardization, stabilizer formulation, lyophilization or liquid filling, sterility and extraneous-agent testing, genetic-stability assessment, and batch release. WOAH requires Classical Swine Fever live vaccines to be manufactured using a seed-lot system and qualified cell culture, with commercial vaccine commonly formulated as a homogeneous lyophilized product. Downstream demand comes from Piglets, Growing and Finishing Pigs, Breeding Sows and Gilts, Breeding Boars, and Others through integrated swine farms, veterinary distributors, and veterinary service networks, supported by cold chain, vaccination-program design, antibody/PCR monitoring, and digital herd-health management.

Segment Insights
By disease type and Dosage Form, PRRS Vaccines represent the most important value segment, with Lyophilized modified-live products being the mainstream technology. A representative Boehringer Ingelheim product contains at least 10^4.8 TCID50 of attenuated VR-2332 strain per dose and is administered at 2 mL intramuscularly. Syva Pyrsvac-183 contains attenuated European strain ALL183 at ≥10^5 TCID50, uses a 2 mL dose, provides onset of immunity at approximately two weeks, and duration of immunity of approximately 16 weeks. Classical Swine Fever live products typically use established attenuated strains such as the C strain; Bioveta provides approximately 100–10,000 TCID50 per dose at 2 mL intramuscularly, with immunity developing within approximately five to seven days.

By Antigen Combination, Monovalent Live Vaccines remain dominant, particularly where PRRS, Classical Swine Fever, or Pseudorabies vaccination programs need to be adjusted independently. Bivalent products reduce administration frequency, while Multivalent Live Vaccines remain a smaller category because of strain-stability, antigen-interference, and registration complexity. By Dosage Form, Lyophilized Live Vaccines dominate because of their relatively favorable long-term stability and are widely used in PRRS, Classical Swine Fever, and Pseudorabies products. Liquid Live Vaccines account for a smaller share and depend more heavily on stable liquid formulations and strict cold-chain handling. Emerging opportunities include 0.2 mL intradermal vaccination, engineered attenuation, DIVA markers, and more stable combination-live platforms.

Downstream Market Opportunities
Piglets represent the largest application because respiratory PRRS is frequently expressed in nursery and young finisher populations, encouraging early immunization from one day, two weeks, or three weeks of age depending on the product. Growing and Finishing Pigs require continuing respiratory-disease control to protect average daily gain and mortality performance. Breeding Sows and Gilts are vaccinated primarily to reduce abortion, premature farrowing, stillbirths, weak-born piglets, and other reproductive losses, with selected products used before breeding or during pregnancy. Use in Breeding Boars is more restricted, and some modified-live PRRS labels specifically advise against vaccination of breeding-age boars. Artificial intelligence is not part of the vaccine itself, but it can integrate PCR, antibody, production, abortion, mortality, and epidemiological data to predict infection risk, optimize vaccination timing, identify vaccine-breakthrough events, and improve batch and animal-level traceability through digital vaccination systems.

Regional Insights
North America is strongly focused on modified-live PRRS products, with Zoetis, MSD Animal Health, Boehringer Ingelheim, and Elanco maintaining established portfolios. The United States and Canada are free from Classical Swine Fever, significantly limiting commercial use of Classical Swine Fever live vaccines. Europe similarly emphasizes PRRSV-1 control, while many countries have WOAH-recognized Classical Swine Fever-free status, making PRRS an important source of live-vaccine demand; HIPRA, Bioveta, and Syva have substantial regional capabilities. Asia has a more complex disease profile, with commercial demand for PRRS, Classical Swine Fever, and Pseudorabies products. Chinese participants include TECON Biology, Harbin Pharmaceutical Group, CAHIC, Jinyu Bio-Technology, Pulike, WINSUN, DHN, HVR, Jilin Zhengye, Wuhan Keqian Biology, and Sinopharm Animal Health. WOAH indicates that Classical Swine Fever remains present principally in parts of Asia, Latin America, Europe, and Africa, creating a strongly regionalized vaccine-demand pattern.

Competitive Landscape Analysis
The product market has substantial barriers in seed-strain resources, cell-culture capability, biosafety, cold-chain management, clinical testing, and regulatory approval. Representative leading players include Zoetis, MSD Animal Health, Boehringer Ingelheim, Ceva Santé Animale, and HIPRA. Zoetis competes through Fostera PRRS, which can be used in pigs one day of age or older and provides at least 26 weeks of respiratory immunity. MSD's Prime Pac PRRS RR uses a convenient 1 mL dose and covers pigs three weeks of age or older and breeding females. Boehringer Ingelheim maintains a broad PRRS portfolio including Ingelvac PRRS MLV, PRRSFLEX EU, and Reprocyc PRRS EU across PRRSV-1 and PRRSV-2 requirements. Ceva differentiates through the reverse-genetics-based Persoporc platform, while HIPRA combines UNISTRAIN PRRS with 0.2 mL needle-free intradermal vaccination and Smart Vaccination digital technologies. Competition is shifting from conventional strains and dose potency toward heterologous cross-protection, genetic stability, low-volume administration, digital traceability, and integrated herd-control programs.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Swine Live Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Zoetis
MSD Animal Health(Merck)
Boehringer Ingelheim
Ceva Santé Animale
Bioveta
HIPRA
Syva
Elanco Animal Health
TECON Biology
VETVACO
Harbin Pharmaceutical Group
CAHIC
Jinyu Bio-Technology
Pulike
WINSUN
DHN
HVRI
Jilin Zhengye
Wuhan Keqian Biology
Sinopharm Animal Health

Segment by Type
PRRS Vaccines
Classical Swine Fever Vaccines
Pseudorabies Vaccines
Others

Segment by Antigen Combination
Monovalent Live Vaccines
Bivalent Live Vaccines
Multivalent Live Vaccines

Segment by Dosage Form
Lyophilized Live Vaccines
Liquid Live Vaccines
Others

Segment by Application
Piglets
Growing and Finishing Pigs
Breeding Sows and Gilts
Breeding Boars
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Swine Live Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Swine Live Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Swine Live Vaccine Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 PRRS Vaccines
1.2.3 Classical Swine Fever Vaccines
1.2.4 Pseudorabies Vaccines
1.2.5 Others
1.3 Market Segmentation by Antigen Combination
1.3.1 Global Swine Live Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032
1.3.2 Monovalent Live Vaccines
1.3.3 Bivalent Live Vaccines
1.3.4 Multivalent Live Vaccines
1.4 Market Segmentation by Dosage Form
1.4.1 Global Swine Live Vaccine Market Size by Dosage Form, 2021 vs 2025 vs 2032
1.4.2 Lyophilized Live Vaccines
1.4.3 Liquid Live Vaccines
1.4.4 Others
1.5 Market Segmentation by Application
1.5.1 Global Swine Live Vaccine Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Piglets
1.5.3 Growing and Finishing Pigs
1.5.4 Breeding Sows and Gilts
1.5.5 Breeding Boars
1.5.6 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Swine Live Vaccine Revenue Estimates and Forecasts (2021-2032)
2.2 Global Swine Live Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Swine Live Vaccine Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Swine Live Vaccine Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 PRRS Vaccines: Market Share by Key Players
3.3.2 Classical Swine Fever Vaccines: Market Share by Key Players
3.3.3 Pseudorabies Vaccines: Market Share by Key Players
3.3.4 Others: Market Share by Key Players
3.4 Global Swine Live Vaccine Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Swine Live Vaccine Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Swine Live Vaccine Market by Antigen Combination
4.2.1 Global Revenue by Antigen Combination (2021-2032)
4.2.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032)
4.3 Global Swine Live Vaccine Market by Dosage Form
4.3.1 Global Revenue by Dosage Form (2021-2032)
4.3.2 Global Revenue-Based Market Share by Dosage Form (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Swine Live Vaccine Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Swine Live Vaccine Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Swine Live Vaccine Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Swine Live Vaccine Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Swine Live Vaccine Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Swine Live Vaccine Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Swine Live Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Swine Live Vaccine Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Swine Live Vaccine Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Swine Live Vaccine Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Swine Live Vaccine Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Zoetis
11.1.1 Zoetis Corporation Information
11.1.2 Zoetis Business Overview
11.1.3 Zoetis Swine Live Vaccine Product Features and Attributes
11.1.4 Zoetis Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.1.5 Zoetis Swine Live Vaccine Revenue by Product in 2025
11.1.6 Zoetis Swine Live Vaccine Revenue by Application in 2025
11.1.7 Zoetis Swine Live Vaccine Revenue by Geographic Area in 2025
11.1.8 Zoetis Swine Live Vaccine SWOT Analysis
11.1.9 Zoetis Recent Developments
11.2 MSD Animal Health(Merck)
11.2.1 MSD Animal Health(Merck) Corporation Information
11.2.2 MSD Animal Health(Merck) Business Overview
11.2.3 MSD Animal Health(Merck) Swine Live Vaccine Product Features and Attributes
11.2.4 MSD Animal Health(Merck) Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.2.5 MSD Animal Health(Merck) Swine Live Vaccine Revenue by Product in 2025
11.2.6 MSD Animal Health(Merck) Swine Live Vaccine Revenue by Application in 2025
11.2.7 MSD Animal Health(Merck) Swine Live Vaccine Revenue by Geographic Area in 2025
11.2.8 MSD Animal Health(Merck) Swine Live Vaccine SWOT Analysis
11.2.9 MSD Animal Health(Merck) Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Swine Live Vaccine Product Features and Attributes
11.3.4 Boehringer Ingelheim Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Swine Live Vaccine Revenue by Product in 2025
11.3.6 Boehringer Ingelheim Swine Live Vaccine Revenue by Application in 2025
11.3.7 Boehringer Ingelheim Swine Live Vaccine Revenue by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Swine Live Vaccine SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Business Overview
11.4.3 Ceva Santé Animale Swine Live Vaccine Product Features and Attributes
11.4.4 Ceva Santé Animale Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Santé Animale Swine Live Vaccine Revenue by Product in 2025
11.4.6 Ceva Santé Animale Swine Live Vaccine Revenue by Application in 2025
11.4.7 Ceva Santé Animale Swine Live Vaccine Revenue by Geographic Area in 2025
11.4.8 Ceva Santé Animale Swine Live Vaccine SWOT Analysis
11.4.9 Ceva Santé Animale Recent Developments
11.5 Bioveta
11.5.1 Bioveta Corporation Information
11.5.2 Bioveta Business Overview
11.5.3 Bioveta Swine Live Vaccine Product Features and Attributes
11.5.4 Bioveta Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.5.5 Bioveta Swine Live Vaccine Revenue by Product in 2025
11.5.6 Bioveta Swine Live Vaccine Revenue by Application in 2025
11.5.7 Bioveta Swine Live Vaccine Revenue by Geographic Area in 2025
11.5.8 Bioveta Swine Live Vaccine SWOT Analysis
11.5.9 Bioveta Recent Developments
11.6 HIPRA
11.6.1 HIPRA Corporation Information
11.6.2 HIPRA Business Overview
11.6.3 HIPRA Swine Live Vaccine Product Features and Attributes
11.6.4 HIPRA Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.6.5 HIPRA Recent Developments
11.7 Syva
11.7.1 Syva Corporation Information
11.7.2 Syva Business Overview
11.7.3 Syva Swine Live Vaccine Product Features and Attributes
11.7.4 Syva Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.7.5 Syva Recent Developments
11.8 Elanco Animal Health
11.8.1 Elanco Animal Health Corporation Information
11.8.2 Elanco Animal Health Business Overview
11.8.3 Elanco Animal Health Swine Live Vaccine Product Features and Attributes
11.8.4 Elanco Animal Health Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.8.5 Elanco Animal Health Recent Developments
11.9 TECON Biology
11.9.1 TECON Biology Corporation Information
11.9.2 TECON Biology Business Overview
11.9.3 TECON Biology Swine Live Vaccine Product Features and Attributes
11.9.4 TECON Biology Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.9.5 TECON Biology Recent Developments
11.10 VETVACO
11.10.1 VETVACO Corporation Information
11.10.2 VETVACO Business Overview
11.10.3 VETVACO Swine Live Vaccine Product Features and Attributes
11.10.4 VETVACO Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Harbin Pharmaceutical Group
11.11.1 Harbin Pharmaceutical Group Corporation Information
11.11.2 Harbin Pharmaceutical Group Business Overview
11.11.3 Harbin Pharmaceutical Group Swine Live Vaccine Product Features and Attributes
11.11.4 Harbin Pharmaceutical Group Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.11.5 Harbin Pharmaceutical Group Recent Developments
11.12 CAHIC
11.12.1 CAHIC Corporation Information
11.12.2 CAHIC Business Overview
11.12.3 CAHIC Swine Live Vaccine Product Features and Attributes
11.12.4 CAHIC Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.12.5 CAHIC Recent Developments
11.13 Jinyu Bio-Technology
11.13.1 Jinyu Bio-Technology Corporation Information
11.13.2 Jinyu Bio-Technology Business Overview
11.13.3 Jinyu Bio-Technology Swine Live Vaccine Product Features and Attributes
11.13.4 Jinyu Bio-Technology Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.13.5 Jinyu Bio-Technology Recent Developments
11.14 Pulike
11.14.1 Pulike Corporation Information
11.14.2 Pulike Business Overview
11.14.3 Pulike Swine Live Vaccine Product Features and Attributes
11.14.4 Pulike Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.14.5 Pulike Recent Developments
11.15 WINSUN
11.15.1 WINSUN Corporation Information
11.15.2 WINSUN Business Overview
11.15.3 WINSUN Swine Live Vaccine Product Features and Attributes
11.15.4 WINSUN Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.15.5 WINSUN Recent Developments
11.16 DHN
11.16.1 DHN Corporation Information
11.16.2 DHN Business Overview
11.16.3 DHN Swine Live Vaccine Product Features and Attributes
11.16.4 DHN Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.16.5 DHN Recent Developments
11.17 HVRI
11.17.1 HVRI Corporation Information
11.17.2 HVRI Business Overview
11.17.3 HVRI Swine Live Vaccine Product Features and Attributes
11.17.4 HVRI Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.17.5 HVRI Recent Developments
11.18 Jilin Zhengye
11.18.1 Jilin Zhengye Corporation Information
11.18.2 Jilin Zhengye Business Overview
11.18.3 Jilin Zhengye Swine Live Vaccine Product Features and Attributes
11.18.4 Jilin Zhengye Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.18.5 Jilin Zhengye Recent Developments
11.19 Wuhan Keqian Biology
11.19.1 Wuhan Keqian Biology Corporation Information
11.19.2 Wuhan Keqian Biology Business Overview
11.19.3 Wuhan Keqian Biology Swine Live Vaccine Product Features and Attributes
11.19.4 Wuhan Keqian Biology Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.19.5 Wuhan Keqian Biology Recent Developments
11.20 Sinopharm Animal Health
11.20.1 Sinopharm Animal Health Corporation Information
11.20.2 Sinopharm Animal Health Business Overview
11.20.3 Sinopharm Animal Health Swine Live Vaccine Product Features and Attributes
11.20.4 Sinopharm Animal Health Swine Live Vaccine Revenue and Gross Margin (2021-2026)
11.20.5 Sinopharm Animal Health Recent Developments

12 Swine Live Vaccine Value Chain and Ecosystem Analysis
12.1 Swine Live Vaccine Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Swine Live Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Swine Live Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Swine Live Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Swine Live Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Swine Live Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Swine Live Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Swine Live Vaccine Revenue, 2025
Table 13. Global Swine Live Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Swine Live Vaccine Companies Headquarters
Table 15. Global Swine Live Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Swine Live Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Swine Live Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 21. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 22. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2021-2026
Table 23. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Swine Live Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Swine Live Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Swine Live Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Swine Live Vaccine Growth Accelerators and Market Barriers
Table 31. North America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Swine Live Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Swine Live Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Swine Live Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Swine Live Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Swine Live Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Zoetis Corporation Information
Table 41. Zoetis Description and Major Businesses
Table 42. Zoetis Product Features and Attributes
Table 43. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Zoetis Revenue Proportion by Product in 2025
Table 45. Zoetis Revenue Proportion by Application in 2025
Table 46. Zoetis Revenue Proportion by Geographic Area in 2025
Table 47. Zoetis Swine Live Vaccine SWOT Analysis
Table 48. Zoetis Recent Developments
Table 49. MSD Animal Health(Merck) Corporation Information
Table 50. MSD Animal Health(Merck) Description and Major Businesses
Table 51. MSD Animal Health(Merck) Product Features and Attributes
Table 52. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 54. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 55. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 56. MSD Animal Health(Merck) Swine Live Vaccine SWOT Analysis
Table 57. MSD Animal Health(Merck) Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Swine Live Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Swine Live Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Bioveta Corporation Information
Table 77. Bioveta Description and Major Businesses
Table 78. Bioveta Product Features and Attributes
Table 79. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Bioveta Revenue Proportion by Product in 2025
Table 81. Bioveta Revenue Proportion by Application in 2025
Table 82. Bioveta Revenue Proportion by Geographic Area in 2025
Table 83. Bioveta Swine Live Vaccine SWOT Analysis
Table 84. Bioveta Recent Developments
Table 85. HIPRA Corporation Information
Table 86. HIPRA Description and Major Businesses
Table 87. HIPRA Product Features and Attributes
Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. HIPRA Recent Developments
Table 90. Syva Corporation Information
Table 91. Syva Description and Major Businesses
Table 92. Syva Product Features and Attributes
Table 93. Syva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Syva Recent Developments
Table 95. Elanco Animal Health Corporation Information
Table 96. Elanco Animal Health Description and Major Businesses
Table 97. Elanco Animal Health Product Features and Attributes
Table 98. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Elanco Animal Health Recent Developments
Table 100. TECON Biology Corporation Information
Table 101. TECON Biology Description and Major Businesses
Table 102. TECON Biology Product Features and Attributes
Table 103. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. TECON Biology Recent Developments
Table 105. VETVACO Corporation Information
Table 106. VETVACO Description and Major Businesses
Table 107. VETVACO Product Features and Attributes
Table 108. VETVACO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. VETVACO Recent Developments
Table 110. Harbin Pharmaceutical Group Corporation Information
Table 111. Harbin Pharmaceutical Group Description and Major Businesses
Table 112. Harbin Pharmaceutical Group Product Features and Attributes
Table 113. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Harbin Pharmaceutical Group Recent Developments
Table 115. CAHIC Corporation Information
Table 116. CAHIC Description and Major Businesses
Table 117. CAHIC Product Features and Attributes
Table 118. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. CAHIC Recent Developments
Table 120. Jinyu Bio-Technology Corporation Information
Table 121. Jinyu Bio-Technology Description and Major Businesses
Table 122. Jinyu Bio-Technology Product Features and Attributes
Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Jinyu Bio-Technology Recent Developments
Table 125. Pulike Corporation Information
Table 126. Pulike Description and Major Businesses
Table 127. Pulike Product Features and Attributes
Table 128. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Pulike Recent Developments
Table 130. WINSUN Corporation Information
Table 131. WINSUN Description and Major Businesses
Table 132. WINSUN Product Features and Attributes
Table 133. WINSUN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. WINSUN Recent Developments
Table 135. DHN Corporation Information
Table 136. DHN Description and Major Businesses
Table 137. DHN Product Features and Attributes
Table 138. DHN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. DHN Recent Developments
Table 140. HVRI Corporation Information
Table 141. HVRI Description and Major Businesses
Table 142. HVRI Product Features and Attributes
Table 143. HVRI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. HVRI Recent Developments
Table 145. Jilin Zhengye Corporation Information
Table 146. Jilin Zhengye Description and Major Businesses
Table 147. Jilin Zhengye Product Features and Attributes
Table 148. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Jilin Zhengye Recent Developments
Table 150. Wuhan Keqian Biology Corporation Information
Table 151. Wuhan Keqian Biology Description and Major Businesses
Table 152. Wuhan Keqian Biology Product Features and Attributes
Table 153. Wuhan Keqian Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Wuhan Keqian Biology Recent Developments
Table 155. Sinopharm Animal Health Corporation Information
Table 156. Sinopharm Animal Health Description and Major Businesses
Table 157. Sinopharm Animal Health Product Features and Attributes
Table 158. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Sinopharm Animal Health Recent Developments
Table 160. Technologies, Platforms and Infrastructure
Table 161. Distributors List
Table 162. Market Trends and Market Evolution
Table 163. Market Drivers and Opportunities
Table 164. Market Challenges, Risks, and Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. PRRS Vaccines Product Picture
Figure 3. Classical Swine Fever Vaccines Product Picture
Figure 4. Pseudorabies Vaccines Product Picture
Figure 5. Others Product Picture
Figure 6. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Monovalent Live Vaccines Product Picture
Figure 8. Bivalent Live Vaccines Product Picture
Figure 9. Multivalent Live Vaccines Product Picture
Figure 10. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Lyophilized Live Vaccines Product Picture
Figure 12. Liquid Live Vaccines Product Picture
Figure 13. Others Product Picture
Figure 14. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Piglets
Figure 16. Growing and Finishing Pigs
Figure 17. Breeding Sows and Gilts
Figure 18. Breeding Boars
Figure 19. Others
Figure 20. Swine Live Vaccine Report Years Considered
Figure 21. Global Swine Live Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 23. Global Swine Live Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global Swine Live Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global Swine Live Vaccine Revenue-Based Market Share Ranking (2025)
Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 27. PRRS Vaccines Revenue-Based Market Share by Player in 2025
Figure 28. Classical Swine Fever Vaccines Revenue-Based Market Share by Player in 2025
Figure 29. Pseudorabies Vaccines Revenue-Based Market Share by Player in 2025
Figure 30. Others Revenue-Based Market Share by Player in 2025
Figure 31. Global Swine Live Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Swine Live Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 33. Global Swine Live Vaccine Revenue-Based Market Share by Dosage Form (2021-2032)
Figure 34. Global Swine Live Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 37. North America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 39. Canada Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 40. Mexico Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 41. Europe Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 43. Europe Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 45. France Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 46. U.K. Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 47. Italy Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 48. Russia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 53. Japan Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 54. South Korea Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Australia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 56. India Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 60. Philippines Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 61. Singapore Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 64. Central and South America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 66. Argentina Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 71. Israel Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 72. Egypt Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 73. South Africa Swine Live Vaccine Revenue (US$ Million), 2021-2032
Figure 74. Swine Live Vaccine Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る